PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 10, 2026Immunology and Cell Biology0 citations

Advances in cellular therapy for cancer: vector design and genome editing

View Full Paper
AMAlexander Donald McLellanUniversity of IndonesiaLDLachlan James DobsonUniversity of OtagoPMPatrick William MarronUniversity of Otago

Key Points

  • This work aims to summarize recent advances in cellular therapies for cancer, focusing on vector design and genome editing.
  • Reviewed progress in CAR T-cell therapeutics and T-cell subset nomenclature.
  • Highlighted key advances in in vivo CAR generation and genome editing technologies.
  • Discussed AI-guided antibody discovery platforms for enhanced immunotherapy.
  • Noteworthy commercial expansion of CAR T-cell therapies despite manufacturing cost challenges.
  • Transitioned to function- and state-based definitions in T-cell nomenclature for better CAR T-cell characterization.
  • Introduction of innovative genome engineering techniques improving cellular therapy efficacy.

Abstract

The year 2025 saw continued scientific progress in cell therapy and further commercial expansion of CAR T-cell therapeutics, alongside notable strategic contractions driven largely by manufacturing cost constraints. The field also benefited from the recent transition in T-cell subset nomenclature toward function- and state-based definitions, enabling more precise characterization of CAR T-cell products. We highlight five key advances, including in vivo CAR generation, next-generation genome engineering and the expanding potential of AI-guided antibody discovery platforms for cellular immunotherapy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

McLellan et al. (2026) studied this question.

synapsesocial.com/papers/69d896566c1944d70ce07b95https://doi.org/10.1111/imcb.70111
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia2025 · 29 citations
  2. 2Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma2023 · 61 citations
  3. 3Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector2025 · 38 citations
  4. 4Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency2025 · 46 citations
  5. 5In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma2025 · 108 citations